This paper is the forty-fifth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Introduction The COVID pandemic prompted a significant increase in the utilization of
telemedicine (TM) for substance use disorder (SUD) treatment. As we transition towards a …

Objective: Extensive exposure to prescription-type opioids has resulted in major harm
worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors …

Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine,
a partial agonist at the mu receptor, are first-line medications in opioid maintenance …

Abstract Background and Aims Limited information exists regarding individual subgroups of
recovery from opioid use disorder (OUD) following treatment and how these subgroups may …

Background There are ongoing concerns regarding pharmaceutical opioid‐related harms,
including overdose and dependence, with an associated increase in treatment demand …

Background The number of pregnant women with opioid use disorder (OUD) has increased
over time. Although effective treatment options exist, little is known about the extent to which …

Purpose A large treatment gap exists for people who could benefit from medications for
opioid use disorder (MOUD). People OUD accessing services in harm reduction and …

Background Knowledge of co-occurring mental disorders (termed 'dual diagnosis') among
patients receiving opioid agonist treatment (OAT) is scarce. This study aimed (1) to estimate …

Objectives Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for
opioid use disorder (OUD) management. However, there is scarce information on LAIB in …